Evidence map›Paper›PMID 38198763›Full record

ArticleOncology research and treatment2024

Management of Patients Undergoing CAR-T Cell Therapy in Germany.

Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. [Management of side effects of CAR T cells].Innere Medizin (Heidelberg, Germany) · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Olaf PenackMedical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Peter DregerMedical Clinic, Department for Haematology and Oncology, University of Heidelberg, Heidelberg, Germany.
Salem AjibDepartment of Medicine 2, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
Francis AyukClinic for Hematology, Stem Cell Transplantation, University Clinic Hamburg Eppendorf, Hamburg, Germany.
Ben-Niklas BaermannDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.
Gesine BugDepartment of Medicine 2, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
Oliver KriegeDepartment of Medicine III, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Madlen JentzschMedical Clinic and Policlinic 1, Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
Guido KobbeDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.
Christian KoeneckeDepartment of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover Medical School, Hannover, Germany.
Mathias LutzHematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Sonja MartinRobert-Bosch-Krankenhaus, Department for Hematology, Oncology and Palliative Care, Stuttgart, Germany.
Paul-Gerhard SchlegelDepartment of Pediatrics, Section of Pediatric Hematology and Oncology, Stem Cell Transplantation (SCT), University Hospital Würzburg, Würzburg, Germany.
Roland SchroersRuhr-University Bochum, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.
Bastian von TresckowDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Vladan VucinicMedical Clinic and Policlinic 1, Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
Marion SubkleweMedical Clinic, Department for Haematology and Oncology, Ludwig-Maximilians-University, Munich, Germany.
Wolfgang BethgeInteernal Medicine II, Hematology and Oncology, University Hospital Tuebingen, Tuebingen, Germany.
Daniel WolffDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Düsseldorf University Hospital · DEGoethe University Frankfurt · DECharité - Universitätsmedizin Berlin · DEEssen University Hospital · DELudwig-Maximilians-Universität München · DEMedizinische Hochschule Hannover · DERobert Bosch Hospital · DERuhr University Bochum · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Heidelberg · DEUniversity Hospital Regensburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEUniversity of Augsburg · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin's lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications.

methodsTo capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers.

resultsWe received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no - or low quality - clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations.

conclusionThe results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome.

Indexed as

Receptors, Chimeric AntigenCell- and Tissue-Based TherapyGermanyHumansImmunotherapy, AdoptivePatientsReceptors, Chimeric AntigenCAR-T cellsComplicationsInfectionsManagementSurvey

Identifiers

PMID38198763
PMCPMC10911269
OpenAlexW4390732155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.